ArticleJournal of neuro-oncology2022

Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.

Vasileios K Kavouridis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.